Basic Cyklokapron Information

• INN (International Nonproprietary Name): Tranexamic acid.
• Brand Names Available In United Kingdom: Cyklokapron; tranexamic acid generics.
• ATC Code: B02AA02.
• Forms & Dosages: 500 mg tablets; injection 100 mg/mL (ampoules 5/10 mL or vials 10 mL); oral solution 100 mg/mL (rare).
• Manufacturers In United Kingdom: Pfizer and multiple generic suppliers (local generics noted in international data).
• Registration Status In United Kingdom: MHRA approved (product-specific details in SPCs).
• OTC / Rx Classification: Prescription only (Rx) in the UK according to public regulatory summaries.

Research Findings (Uk And Eu) 2022–2025

Worried that tranexamic acid studies are inconsistent or that safety is under‑reported?

Systematic reviews and national audits from 2022–2025 reaffirm tranexamic acid as an effective antifibrinolytic to reduce blood loss and the need for transfusion in elective and emergency surgery.

Evidence summaries also support use of oral tranexamic acid for heavy menstrual bleeding with improvements in measured blood loss and patient‑reported outcomes across multiple cohorts.

UK peri‑operative audits report reduced intra‑operative transfusion rates where TXA is used according to local protocols.

European registries corroborate low absolute rates of thromboembolic complications when contraindications are respected and renal dosing is applied.

Key safety signals remain consistent: seizures associated with high intravenous doses, accumulation in renal impairment, and rare visual disturbances.

Practical takeaway for UK prescribers: align dosing with MHRA guidance and local NHS trust protocols and adjust doses for renal function.

Clinicians should consult SPCs, NICE and MHRA updates when preparing local guidelines and when citing evidence-grade recommendations.

Clinical Effectiveness In The Uk

Does TXA actually change outcomes in NHS practice?

Multiple NHS trusts report meaningful reductions in peri‑operative blood loss and fewer transfusions when tranexamic acid is included in enhanced recovery and bleeding protocols.

For heavy menstrual bleeding, NHS patient outcomes show symptom improvement and fewer surgical interventions when oral tranexamic acid 500 mg is used for up to five days per cycle.

Patient‑reported outcome measures collected via NHS portals indicate improved quality of life within one to two cycles for many women using tranexamic acid for menorrhagia.

Safety monitoring via the MHRA Yellow Card scheme and local governance highlights rare thrombotic events, mostly in patients with pre‑existing risks or inadequate renal dosing.

Clinicians should combine product form data such as Cyklokapron 500 mg tablets and tranexamic acid injection 100 mg/mL with individual patient risk assessment and document rationale in shared records between GP, hospital and community pharmacy.

Indications And Expanded Uses (Mhra & Nhs Practice)

Which situations in NHS practice call for tranexamic acid, and when is use off‑label?

MHRA‑approved indications align with major EU labels and include control of bleeding where antifibrinolytic therapy is appropriate, such as surgical bleeding and dental or haemophilia procedures.

Common NHS uses include bleeding prophylaxis in surgery and treatment of heavy menstrual bleeding.

Off‑label but established uses in NHS practice include topical TXA for epistaxis and local use in ENT or dental surgery, and occasional specialist use of oral TXA for hereditary angioedema prophylaxis.

1. Surgical Bleeding: Typical NHS regimen — IV 1–1.5 g at induction, repeat 6–8 hourly per local protocol.
2. Heavy Menstrual Bleeding: Typical NHS regimen — oral 500 mg two to three times daily for up to five days of the cycle.
3. Topical/Mucosal Bleeding (Off‑Label): Typical NHS regimen — topical application or 500 mg PO 2–3× daily, depending on specialist advice.
4. Hereditary Angioedema (Specialist Use): Typical regimen — oral 1,000–1,500 mg 2–3× daily under specialist supervision.

Prescribers must document consent for off‑label use, check renal function, and review concurrent thrombosis risk before initiating therapy.

Composition And Brand Landscape (Uk Focus)

What should pharmacies stock and what will patients recognise on the label?

The active ingredient is tranexamic acid (INN), commonly marketed in the UK as Cyklokapron and as generics in 500 mg tablets and injectable 100 mg/mL presentations.

ATC classification places tranexamic acid in B02AA02 as an antifibrinolytic.

For pharmacy SEO and e‑commerce, common product descriptors include “Cyklokapron 500 mg tablets” and “tranexamic acid injection 1 g/10 mL”.

Stocking decisions in community pharmacies reflect prescription demand and NHS repeat patterns, with electronic prescribing increasing generic substitution.

Contraindications And Special Precautions (High‑Risk Groups)

Which patients should never receive tranexamic acid, and who needs extra caution?

• Absolute Contraindications: known hypersensitivity to tranexamic acid; active intravascular clotting such as DVT or PE; history of convulsions or seizures; history of acquired defective colour vision (particularly with injection).
• Special Precautions: renal impairment requires dose reduction as TXA is renally excreted.
• Pregnancy And Breastfeeding: use only if benefits outweigh risks and follow obstetric protocols.
• Patients On Combined Hormonal Contraception Or With Thrombophilia: assess baseline thrombotic risk before prescribing.
• Elderly Patients: adjust dosing only based on renal function, not age alone.

Pharmacists should flag high‑risk prescriptions via NHS electronic systems and advise urgent review if thrombotic symptoms develop.

Dosage Guidelines (Nhs‑Aligned)

How should tranexamic acid be dosed across common NHS indications?

Electronic prescribing prompts for creatinine and allergy checks should be used in NHS systems.

Community pharmacists should advise on missed doses: take when remembered but do not double the next dose.

Interactions Overview (Drugs, Food, Mhra Reports)

Will tranexamic acid interact with my other medicines or diet?

Clinically relevant interactions include increased thrombosis risk when combined with systemic procoagulants such as factor concentrates or anti‑inhibitor coagulant complexes.

Concurrent oestrogen‑containing medications (combined oral contraceptives, HRT) add baseline thrombotic risk and warrant monitoring.

No major food interactions are established, though alcohol may worsen dizziness or gastrointestinal side effects.

• High‑Risk Medicines: factor IX complex, anti‑inhibitor coagulant, systemic procoagulants, and cautions with concurrent hormone therapy.
• Neuroactive Drugs: check co‑medications in patients at risk of seizures because high IV doses of TXA have been associated with seizures.

MHRA Yellow Card reports and local incident logs emphasise caution with prothrombotic agents and in patients with prior thromboembolic disease.

Pharmacy teams should record interactions in medication records and advise the prescriber when initiating tranexamic acid.

Cultural Perceptions And Patient Habits In The Uk

What do UK patients ask about when tranexamic acid enters the conversation?

Community forums and NHS patient portals show generally positive attitudes to tranexamic acid for heavy periods and dental procedures.

Many patients seek pharmacist counselling before accepting a prescription and value concise, practical advice.

Urban areas with more private clinics report more off‑label topical use, while rural communities rely on GP prescribing and hospital protocols.

• Common Patient Concerns: safety with contraception, need for blood tests, and seizure or clot risk.
• Typical Habits: checking NHS 111 or forum posts before contacting a GP; visiting a pharmacy for an initial chat.

Pharmacy counselling should be patient‑centred: explain benefits, common side effects, when to seek urgent help, and local support options such as gynaecology or sexual health services.

Availability And Pricing Patterns (Boots, Lloyds, Nhs Differences)

How accessible is Cyklokapron across the UK and what will patients pay?

Cyklokapron and generics are widely registered in the UK with MHRA approval and are dispensed through community pharmacies such as Boots and LloydsPharmacy on NHS prescription.

England has a fixed NHS prescription charge (with prepayment options) whereas Scotland, Wales and Northern Ireland largely abolished routine charges, which affects patient out‑of‑pocket cost.

In our online pharmacy, cyklokapron is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Private prescriptions and clinic supplies show variable retail pricing and online vendors require verified e‑prescribing for lawful supply.

Comparable Medicines And Prescribing Preferences

What are the alternatives and why do clinicians usually pick tranexamic acid?

Aminocaproic acid (EACA) and topical haemostatic agents are alternatives, but tranexamic acid is often preferred for potency, cost‑effectiveness and strong trial data in trauma, surgery and gynaecology.

NHS formularies commonly list tranexamic acid as the first‑line antifibrinolytic, with choice influenced by indication, availability and contraindications.

Pharmacists advising prescribers should highlight renal function, seizure history and thrombosis risk when discussing switches between agents.

Frequently Asked Questions

Q1: Is Cyklokapron safe for heavy periods?

A: Yes for most people; it reduces bleeding and is widely used in NHS practice but avoid if you have active clotting or a seizure history.

Q2: Do I need a blood test before starting?

A: Not routinely, but check renal function if you have kidney disease or are elderly.

Q3: Can I take tranexamic acid with my contraceptive pill?

A: Generally yes, but combined hormonal contraception increases baseline thrombotic risk so discuss with your GP if you have other risk factors.

Q4: What if I miss a dose?

A: Take as soon as remembered and do not double up the next dose.

Signpost: contact NHS 111, your GP, or local gynaecology services for ongoing care.

Guidelines For Proper Use (Pharmacy Counselling & Nhs Portals)

What should dispensing teams cover when handing out tranexamic acid?

Confirm indication, dose (see dosage table), allergy and seizure history, renal function and concurrent prothrombotic medications before supply.

Advise on administration: tablets with water and IV administration only in supervised settings.

Storage: store tablets and injections below 25°C and keep protected from light; do not freeze.

When To Seek Urgent Care: swelling, chest pain, sudden leg pain, new visual changes or seizures require immediate medical attention.

• Dispensing Checklist: indication confirmed; dose and duration clear; allergy and renal checks done; counselling recorded in NHS electronic record.
• Adverse Signs Versus Expected Side‑Effects: expected—headache, nausea, mild dizziness; urgent—visual disturbance, thrombotic symptoms, convulsions.

Encourage Yellow Card reporting for suspected adverse reactions and arrange GP follow‑up after an initial course for menorrhagia or post‑op review if used prophylactically.

Delivery Across United Kingdom

Final Notes For Clinicians And Pharmacists

Tranexamic acid is a well‑established antifibrinolytic with broad utility across surgery, trauma and gynaecology when used within licensed indications and local protocols.

Product names available in the UK include Cyklokapron and multiple generics in 500 mg tablet and 100 mg/mL injection presentations.

Key safety considerations are seizure risk with large IV doses and accumulation in renal impairment; visual disturbances and thromboembolic events remain rare but important.

Always check the SPC for specific product details and consult NICE, MHRA and local trust guidance when forming prescribing policies.